GlucoTrack Inc.

03/13/2026 | Press release | Distributed by Public on 03/13/2026 14:06

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On March 12, 2026, Glucotrack, Inc. (the "Company"), held a special meeting of its stockholders (the "Special Meeting"). As of January 28, 2026, the record date for the Special Meeting, there were 1,011,279 shares of common stock, par value $0.001 per share of the Company (the "Common Stock"), issued and outstanding, entitled to 1,011,279 votes in the aggregate. Of the 1,011,279 votes that were eligible to be cast by the holders of Common Stock at the Special Meeting, 446,348 votes, or approximately 44.1% of the total, were represented at the meeting in person or by proxy, constituting a quorum. The proposals listed below are described in more detail in the Company's definitive proxy statement, which was filed with the Securities and Exchange Commission on February 9, 2026 (the "Proxy Statement"). Capitalized terms not defined herein shall have the meanings ascribed to them in the Proxy Statement. A summary of the proposals presented to and considered by the stockholders of the Company and the voting results at the Special Meeting are set forth below:

The Nasdaq Stock Issuance (ELOC) Proposal - To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of Common Stock, to Sixth Borough Capital Fund, LP ("Sixth Borough"), pursuant to that certain purchase agreement, dated September 11, 2025, by and between the Company and Sixth Borough (the "Purchase Agreement"), which shares may represent more than 20% of the Company's issued and outstanding Common Stock as of the date of the Purchase Agreement. The votes regarding this proposal were as follows:

Votes For Votes Against Abstentions Broker Non-Votes
126,610 18,261 7,846 293,631

The Nasdaq Stock Issuance (Warrants) Proposal - To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of Common Stock issuable upon the exercise of 2,067,182 common warrants to purchase Common Stock, issued to the investor (the "Investor") in a private placement that closed on December 31, 2025 (the "Private Placement").

In accordance with Nasdaq Listing Rule 5635 and IM-5635-2, "Interpretative Material Regarding the Use of Share Caps to Comply with Rule 5635," 100,591 shares of Common Stock that were issued upon exercise of pre-funded warrants issued in connection with the Private Placement prior to the record date were not entitled to vote such shares (the "Excluded Shares") with respect to the Nasdaq Stock Issuance (Warrants) Proposal. Any votes cast "FOR" the Nasdaq Stock Issuance (Warrants) Proposal attributable to any of the Excluded Shares were disregarded for purposes of determining whether the proposal was approved. To comply with Nasdaq rules, we instructed the inspector of elections to conduct separate tabulations that subtract the Excluded Shares from the total number of shares voted in favor of this proposal to determine whether the proposal had been adopted in accordance with applicable Nasdaq rules, which require a majority of the shares of Common Stock that are present or represented by proxy at the Special Meeting and entitled to vote on such proposal (other than the votes required to be excluded in accordance with Nasdaq rules) to be voted in favor of the applicable proposal. Accordingly, The votes regarding this proposal were as follows:

Votes For Votes Against Abstentions Broker Non-Votes Excluded Shares
26,134 18,151 7,841 293,631 100,591

The Auditor Ratification Proposal - To ratify the previous appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the year ended December 31, 2025. The votes regarding this proposal were as follows:

Votes For Votes Against Abstentions Broker Non-Votes
431,871 4,108 10,369 -

The Adjournment Proposal - To adopt and approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if it is determined by the Company that more time is necessary or appropriate to approve the Nasdaq Stock Issuance (ELOC) Proposal, the Nasdaq Stock Issuance (Warrants) Proposal, or the Auditor Ratification Proposal at the Special Meeting (the "Adjournment Proposal"). The Adjournment Proposal was not presented at the Special Meeting since the Nasdaq Stock Issuance (ELOC) Proposal, the Nasdaq Stock Issuance (Warrants) Proposal, and the Auditor Ratification Proposal each received sufficient favorable votes to be adopted.

GlucoTrack Inc. published this content on March 13, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 13, 2026 at 20:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]